Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections

Inclusion Criteria: * Adult (≥ 18 years) * Hospitalized patient with clinically significant monomicrobial UTI * Complicated UTI due to ESBL producing enterobacteriaceae (pyelonephritis, prostatitis or renal abscess) requiring parenteral antimicrobial therapy * Susceptibility to temocillin and carbapenem as evidenced by testing results * For woman able to procreate: negative pregnancy test and use of an effective method of contraception (abstinence, oral contraceptives, intra-uterine device, diaphragm with spermicide and condom). All forms of hormonal contraception are acceptable * Signed informed consent by patient himself (able or under curatorship) or his legal representative (patient unable to give his consent or under tutorship) * Patient affiliated to the social security system Exclusion Criteria: * Patient infected with a bacteria which is not an ESBL-producing enterobacteriaceae. * Polymicrobial infection. * Hypersensitivity and/or previous intolerance to carbapenem or temocillin, or penicillins or any other beta-lactam. * Patient with a contraindication to any of the drugs to be used in research * Patient presenting another site of infection than urinary (except onset of bacteraemia from urinary tract origin due to Gram negative bacteria). * Woman who is pregnant, breastfeeding, or expecting to conceive at any time during the study (pregnancy test will be conducted for woman without menopause). * Palliative care of life expectancy \< 90 days. * Ongoing empirical treatment of the urinary tract infections with carbapenem or temocillin \> 24 hours before randomization * Delay in randomization \> 48 hours after identification of ESBL producing enterobacteriaceae in urinary and/or blood culture. * Participation in other clinical trial for the infection.